Sign in
Taking people in South KoreaPhase 4

Tests macitentan with dapagliflozin in heart failure and lung blood pressure

Tests macitentan plus dapagliflozin in adults with heart failure and high lung blood pressure.

Key facts

Who runs it
Gachon University Gil Medical Center
Where
Busan, Chungju, Daegu, Daejeon, Gwangju, Incheon, Seoul, Wŏnju, and Yangsan, South KoreaSee the 15 sites
Trial code
Registry title
Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)
Status
Recruiting
Phase
Phase 4
People taking part
64 people, planned
Started
24 Nov 2025
Expected to end
30 Sept 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Combination therapy
  • Monotherapy
Record updated
3 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with heart failure (mildly reduced or preserved ejection fraction) and combined pre- and post-capillary pulmonary hypertension. It tests macitentan plus dapagliflozin against dapagliflozin plus placebo.

Age
19 years or older
Sex
Men and women can both join.
Disease stage
Heart failure with LVEF greater than 40% on echocardiogram within 12 weeks before screening, with combined pre- and post-capillary pulmonary hypertension (WHO Group 2). Right heart catheterisation within 48 weeks before screening must show mPAP > 20 mmHg, PVR > 2 Wood units and PAWP > 15 mmHg. WHO functional class II or III.
Earlier treatment
If taking renin-angiotensin system inhibitors, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors or ivabradine, the dose must have been stable for at least 3 months. Within 4 weeks before screening, no calcium channel blockers, endothelin receptor antagonists, PDE5 inhibitors, riociguat, prostacyclin analogs or receptor agonists, or activin signaling inhibitors.

Main reasons for not taking part

  • Pregnant or breastfeeding women
  • Type 1 or secondary diabetes, or metabolic acidosis such as diabetic ketoacidosis
  • Pulmonary hypertension of WHO Group 1, 3, 4 or 5
  • Heart attack, bypass surgery or stent procedure within 3 months before screening
  • eGFR 30 mL/min/1.73 m² or lower, or AST or ALT 2.5 times the upper limit of normal or higher

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • <Screening Visit (Visit 1)>
  • A male or female adults aged 19 years or older in South Korea
  • LVEF greater than 40% on echocardiogram performed within 12 weeks prior to screening
  • Presence of heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF) accompanied by combined pre- and post-capillary pulmonary hypertension (CpcPH)
  • Meeting all of the following criteria on RHC performed within 48 weeks prior to screening:; mPAP > 20 mmHg; PVR > 2 Wood units (WU); PAWP > 15 mmHg
  • World Health Organization Functional Class (WHO-FC) II or III at the time of screening
  • If taking any of the following medications at the time of screening, the participant must have been on a stable dose for at least 3 months:; Renin-angiotensin system inhibitors; Beta-blockers; Mineralocorticoid receptor antagonists (aldosterone antagonists); Sodium-glucose cotransporter-2 (SGLT2) inhibitors; Ivabradine; <Baseline Visit (Visit 2)>
  • World Health Organization Functional Class (WHO-FC) II or III at the time of baseline visit

Who cannot take part

  • Pregnant or breastfeeding women, or those who do not agree to use at least two appropriate contraceptive methods* (self or partner) during the clinical trial period and for 30 days after the last administration of the investigational medicinal product (for male participants, those who do not agree to refrain from sperm donation); *: a. Surgical sterilization (e.g., vasectomy) or intrauterine device (IUD; copper IUD or hormone-releasing intrauterine system), b. Non-oral hormonal contraceptive or spermicide in combination with a barrier method, c. Cervical cap or diaphragm used in combination with a male condom
  • Participants who meet the following criteria on RHC performed within 12 weeks prior to screening:; PAWP ≤ 15 mmHg
  • History of any of the following medical conditions, surgeries, or procedures:; Myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention (PCI) within 3 months prior to screening; Uncontrolled tachycardia (>110 bpm) due to atrial fibrillation or atrial flutter; History of heart transplantation or implantation of a ventricular assist device, or planned to undergo such procedures
  • Urinary tract infection, genital infection (including fungal infections), or voiding disorder within 24 weeks prior to screening
  • Participation in another clinical trial involving administration/application of an investigational medicinal product or medical device within 3 months prior to screening; <Baseline Visit (Visit 2)>
  • Known hypersensitivity to the active ingredients (Macitentan, Dapagliflozin) or any excipients of the investigational medicinal product
  • Participants with type 1 diabetes mellitus or secondary diabetes mellitus
  • Participants diagnosed with pulmonary hypertension other than WHO Group 2 pulmonary hypertension (i.e., WHO Group 1, 3, 4, or 5); Group 1: Pulmonary arterial hypertension; Group 3: Pulmonary hypertension associated with lung diseases and/or hypoxia; Group 4: Chronic thrombo-embolic pulmonary hypertension; Group 5: Pulmonary hypertension with unclear and/or multifactorial mechanisms
  • Known hypersensitivity to soybean oil or history of soybean oil allergy
  • Known hypersensitivity to soy or peanuts
  • Participants who, upon re-confirmation of inclusion/exclusion criteria at the baseline visit, have any disqualifying condition
  • Any other condition that, in the opinion of the investigator, makes the participant unsuitable for participation in this clinical trial
  • History of taking any of the following medications within 4 weeks prior to screening:; Calcium channel blockers; Endothelin receptor antagonists; Phosphodiesterase type 5 inhibitors (PDE5i); Riociguat; Prostacyclin (PC) analogs or prostacyclin receptor agonists; Activin signaling inhibitors
  • eGFR ≤ 30 mL/min/1.73 m² or AST or ALT ≥ 2.5 × ULN
  • Hemoglobin < 9 g/dL at the time of screening
  • Participants with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
  • <Screening Visit (Visit 1)>
  • Participants with metabolic acidosis, such as diabetic ketoacidosis

Where in South Korea

  • Pusan National University HospitalBusan, South KoreaContact: Wook-Jin Chung, MD, PhDTaking people
  • Chungbuk National University HospitalChungju, South KoreaContact: Wook-Jin Chung, MD, PhDNot yet recruiting
  • Keimyung University Dongsan HospitalDaegu, South KoreaContact: Wook-Jin Chung, MD, PhDTaking people
  • Chungnam National University HospitalDaejeon, South KoreaContact: Wook-Jin Chung, MD, PhDTaking people
  • Chonnam National University HospitalGwangju, South KoreaContact: Wook-Jin Chung, MD, PhDTaking people
  • Gachon University Gil HospitalIncheon, South KoreaContact: Wook-Jin Chung, MD,PhDTaking people
  • Incheon Sejong HospitalIncheon, South KoreaContact: Wook-Jin Chung, MD, PhDNot yet recruiting
  • Asan Medical CenterSeoul, South KoreaContact: Wook-Jin Chung, MD, PhDTaking people
  • Koera University Guro HospitalSeoul, South KoreaContact: Wook-Jin Chung, MD, PhDNot yet recruiting
  • Samsung Medical CenterSeoul, South KoreaContact: Wook-Jin Chung, MD, PhDNot yet recruiting
  • Seoul National University HospitalSeoul, South KoreaContact: Wook-Jin Chung, MD, PhDTaking people
  • The Catholic University of Korea, Seoul St.MarySeoul, South KoreaContact: Wook-Jin Chung, MD, PhDTaking people
  • Yonsei University Health System, Severance HospitalSeoul, South KoreaContact: Wook-Jin Chung, MD, PhDNot yet recruiting
  • Yonsei University Wonju Severance Christian HospitalWŏnju, South KoreaContact: Wook-Jin Chung, MD, PhDTaking people
  • Pusan National University Yangsan HospitalYangsan, South KoreaContact: Wook-Jin Chung, MD, PhDNot yet recruiting

About the trial

What the trial wants to find out

This clinical trial will evaluate whether combination therapy with Dapagliflozin + Macitentan improves outcomes compared to Dapagliflozin + placebo in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH).

Read full original descriptionShow less

The study will measure changes in pulmonary vascular resistance, NT-proBNP, 6-minute walk distance, and quality of life (KCCQ scores) over 24 weeks.

Participants will be randomly assigned to one of two groups, take study medication for 24 weeks, and undergo regular clinical, laboratory, and safety assessments.

The 2 groups in the trial

  • Combination therapy groupTreatment being tested

    Maciten Tab. 10mg

    Treatment: Combination therapy

  • Monotherapy groupPlacebo, for comparison

    Dapozin Tab. 10mg or 5mg

    Treatment: Monotherapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-Blind, Exploratory Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)
Plain-language title
Tests macitentan with dapagliflozin in heart failure and lung blood pressureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
3 April 2026